Orchid to acquire US-based marketing company Karalex Pharma

The Chennai-based generic pharma major, Orchid Chemicals & Pharmaceuticals Ltd has entered an agreement to acquire Karalex Pharma, a US-based generic marketing and sales service company, through an all-cash deal for an undisclosed amount. The transaction is expected to close by this month subject to customary closing conditions. Through this acquisition, Orchid has created its presence in the front-end US market and will be able to reach its generic products to the US customers directly.

Headquartered in New Jersey, Karalex Pharma is a leading provider of generic pharmaceuticals focused exclusively on the US healthcare market. Orchid is a leading pharmaceutical company involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals.

On Thursday, Orchid's shares ended 4.61% up at Rs151 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.59% up at 16,922 points.

User

Rollbacks & about-turns: Will the government sink the proposed public float norms?

The holy cows of our corporate world do not want the proposed minimum 25% public float norms to...

Premium Content
Monthly Digital Access

Subscribe

Already A Subscriber?
Login
Yearly Digital+Print Access

Subscribe

Moneylife Magazine Subscriber or MSSN member?
Login

Yearly Subscriber Login

Enter the mail id that you want to use & click on Go. We will send you a link to your email for verficiation
HCC raises Rs295crore by selling 74% stake in 247 Park

The funds will be utilised to reduce debt

IL&FS Milestone Fund has bought 74% stake in Hindustan Construction Co Ltd's (HCC) '247 Park' project for Rs575crore. The deal was signed on Wednesday. HCC has already received Rs121crore as token amount when signing the deal.

The property is valued at Rs775crore. "The equity valuation of this property is Rs400crore and the company will get Rs295crore from the sale of a 74% stake in the project. The funds will be used to reduce the company's debt which currently stands at Rs380crore," said Praveen Sood, group chief financial officer, HCC.

"We have bought 74% stake in HCC's 247 Park," confirmed Ashish Joshi, managing partner-real estate, Milestone Capital Advisors Pvt Ltd.

The corporate park is built on a 1.8-million sq ft plot in Vikhroli (central Mumbai). It includes three towers for housing service and retail businesses. It also has a business centre, ATMs, banks, a gymnasium, food courts and high-end restaurants.

HCC has already leased 85% of the space in 247 Park to various corporates. The project is under HCC Real Estate Ltd. (HREL) which is a 100% subsidiary of HCC.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)